Winston-Salem, North Carolina Feb 02, 2010
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the 12th Annual BIO CEO and Investor Conference at The Waldorf Astoria hotel in New York City on Tuesday, February 9, 2010 at 3:00 p.m. Eastern Standard Time.
Dr. deBethizy’s presentation will be webcast and accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept's website for at least two weeks following the presentation date.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops novel NNR Therapeutics (TM) for the treatment of central nervous system diseases and disorders in support of its vision of building health and restoring independence for patients. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has two collaborations with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept’s news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 362-3087
Email: linnmich@comcast.net